MED

Wellness company Medifast (NYSE:MED) reported Q3 2026 results topping the market’s revenue expectations, but sales fell by 19.4% year on year to $72.05 million.

Medifast’s third quarter results were marked by a positive market response, as the company’s revenue slightly exceeded Wall Street’s expectations despite a substantial year-over-year decline.

Shares of wellness company Medifast (NYSE:MED) jumped 6.2% in the afternoon session after the company, in a press release, reported third quarter results, with sales exceeding Wall Street's expectations.

Medifast stock inched 3.1% higher to US$12.49 on the first full trading day after its Q3 2026 report, a modest move for what was a far more dramatic income statement.

MED tops Q3 earnings expectations as coach productivity jumps 54.1% and margins expand, despite declining revenues and a shrinking coach network.

CEO Johnson targets Q4 profitability amid record coach productivity gains.

Moby summary of Medifast, Inc.'s Q3 2026 earnings call

Medifast (NYSE:MED) reported third-quarter 2026 revenue of $72 million, down 19.4% from a year earlier, as the company continued to face a sharp decline in its active earning coach base.

Wellness company Medifast (NYSE:MED) reported Q3 2026 results beating Wall Street’s revenue expectations, but revenue fell by 19.4% year on year to $72.05 million.

Medifast (MED) delivered earnings and revenue surprises of +52.50% and +5.89%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

BALTIMORE (AP) — BALTIMORE (AP) — Medifast Inc. (MED) on Monday reported a loss of $17.